🏛️ Verified NIH Record • Updated 2024-05-06

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) (NCT05859217)

🟡 Not Yet Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Jun Zhang, MD, PhD

🩺 Plain-English Summary (8th-Grade Level)

NSCLC patients with low expression level of PD-L1, esp. those with its level less than 1%, do not derive much benefit from anti-PD-1/L1 therapy (e.g. atezoilzumab). In this study, investigators hypothesize that the combination of cabozantinib (a multi-kinase inhibitor) and atezolizumab will result in better therapeutic value.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (17 items) and avoid the listed exclusions (36 items).

Location: The University of Kansas Cancer Center - Westwood — Kansas City, Kansas

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • EXCLUSION CRITERIA:
  • Simultaneously enrolled in any therapeutic clinical trial
  • Current or anticipating use of other investigational agents while participating in this study
  • Treatment with investigational therapy within 28 days prior to initiation of study treatment
  • Diagnosed with a psychiatric illness or is in a social situation that would limit compliance with study requirements
  • Active Grade 3 (per the NCI CTCAE, Version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment
  • Patients harboring targetable mutations (e.g., EGFR, ALK and BRAF, etc.) who have not had at least one frontline targeted therapy fail, or have received other systemic therapies (e.g. chemotherapy, immunotherapy, etc.)
  • Patients with carcinomatous meningitis (leptomeningeal metastasis)
  • Undergone major surgery within 2 weeks prior to the start of study regimen, or has not achieved complete wound healing
  • Presence of another cancer with disease manifestations or therapy that could adversely affect participant safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results. Otherwise, patients can be considered eligible, for example, locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
  • Prior treatment with cabozantinib and/or atezolizumab.
  • Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (4 Sites)

  • The University of Kansas Cancer Center - Westwood — Kansas City, Kansas
  • The University of Kansas Cancer Center - Indian Creek — Overland Park, Kansas
  • The University of Kansas Cancer Center - North — Kansas City, Missouri
  • The University of Kansas Cancer Center - Lee's Summit — Lee's Summit, Missouri

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗